Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

ConditionsCentral Nervous System Lymphoma Hematopoietic and Lymphoid Cell Neoplasm Leukemia Lymphoma Plasma Cell Myeloma Secondary Central Nervous System Lymphoma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorM.D. Anderson Cancer Center

About this trial

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.

Eligibility criteria

Qualifiers

Age 18 years or older

Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma [PCNSL], secondary central nervous system lymphoma [SCNSL], leukemia, myeloma)

Proficient and capable of completing tests in English

Patients with claustrophobia are eligible if the claustrophobia is managed with medication

Disqualifiers

None

Trial design

Treatments tested in this trial

Magnetic Resonance Imaging
Neurocognitive Assessment
Quality-of-Life Assessment
Questionnaire Administration

Treatment groups

100 Participants

are divided into 1 treatment group

Locations

M D Anderson Cancer Center77030, HoustonTexas, United States

Sponsors and collaborators

M.D. Anderson Cancer Center

Lead sponsor

Source ClinicalTrials.gov